瑞舒伐他汀对肥胖型2型糖尿病合并高脂血症患者高敏C反应蛋白及血脂的影响

Effects of Rosuvastatin on High-sensitivity C-reactive Protein and Lipid Profile in Patients with Obese Type 2 Diabetes with Hyperlipidemia

目的观察瑞舒伐他汀对肥胖型2型糖尿病合并高脂血症患者血清高敏C反应蛋白(hs-CRP)及血脂水平的影响。方法将80例肥胖型2型糖尿病合并高脂血症患者随机分为观察组及对照组,每组40例。2组均按照2型糖尿病治疗指南标准给予常规降糖治疗,观察组在常规治疗基础上,给予10 mg.d-1的瑞舒伐他汀治疗。治疗6个月,检测2组治疗前后血清hs-CRP和血脂水平。结果观察组血清hs-CRP、LDL-C、TG、TC水平与治疗前相比明显降低,差异有统计学意义(P<0.05),血清HDL-C水平与治疗前相比升高,但差异无统计学意义(P>0.05);对照组治疗后血清hs-CRP水平降低,但与治疗前相比差异无统计学意义(P>0.05),血清LDL-C、HDL-C、TG、TC水平与治疗前相比差异无统计学意义(P>0.05)。2组治疗后相比:观察组血清hs-CRP、LDL-C、TG及TC水平均明显低于对照组,差异有统计学意义(P<0.05);血清HDL-C水平与对照组相近,差异无统计学意义(P>0.05)。结论瑞舒伐他汀可降低肥胖型2型糖尿病合并高脂血症患者超敏C反应蛋白及血脂水平。

Objective To evaluate the effects of rosuvastatin on high-sensitivity C-reactive protein（hs-CRP）and lipid profile in patients with obese type 2 diabetes mellitus（T2DM） and hyperlipidemia.Methods A total of 80 patients with obese T2DM and hyperlipidemia were randomly assigned to receive conventional diabetes therapy alone（control group,n=40）or in combination with rosuvastatin 10 mg once daily（observation group,n=40）.Patients were followed up for 6 months.The levels of hs-CRP and blood lipid were determined before and after treatment.Results Rosuvastatin treatment significantly decreased levels of hs-CRP,low-density lipoprotein cholesterol（LDL-C）,triglyeride（TG）and total cholesterol（TC）（P0.05）,but no obviously increased levels of high-density lipoprotein cholesterol（HDL-C）（P0.05）.However,conventional diabetes therapy had no significant effects on levels of hs-CRP and blood lipid（P0.05）.Compared with control group,levels of hs-CRP,LDL-C,TG and TC significantly decreased in observation group after treatment（P0.05）.No significant differences in HDL-C levels were found between the two groups（P0.05）.Conclusion Rosuvastatin treatment can reduce levels of hs-CRP and blood lipid in patients with obese T2DM and hyperlipidemia.